- Home
- / Anchiano Therapeutics
Anchiano Therapeutics
Stock Price
$16.6
2021-05-17
Market Capitalization
$34.9 M
2021-05-17
Anchiano Therapeutics Summary
Company Summary
- Overview
- Anchiano Therapeutics is a clinical-stage biotechnology company that develops gene therapies to treat early-stage bladder cancer. It is primarily developing Inodiftagene that is in various clinical trials for the treatment of non-muscle-invasive bladder cancer.
- Type
- Public
- Status
- Closed
- Founded
- 2004
- HQ
- Cambridge, MA, US | view all locations
- Website
- https://www.anchiano.com/
- Cybersecurity rating
Table of Contents
Key People
Andrew Fine, Chief Financial Officer
Ron Knickerbocker, Senior Vice President of Clinical Development and Data Sciences
Operating MetricsView all
Phase I Trials Products
2
FY, 2018
Phase II Trials Products
7
FY, 2018
Phase III Trials Products
1
FY, 2018
LocationsView all
1 location detected
Cambridge, MA HQ
United States
One Kendall Square Building 1400E Suite 14-105
Anchiano Therapeutics Financials
Summary Financials
- Net income (FY, 2017)
- $9.8M
- Cash (FY, 2017)
- $1.5M
- EBIT (FY, 2017)
- ($9.4M)
Competitors and Similar Companies
Footer menu
Product
- Intelligence Suite
- Supplier Intelligence Platform
- Craft Intelligence Portal
- Craft API
- Craft for Teams
- Supplier Intelligence Platform
- Craft Alerts
- Craft N-Tier Mapping
- Craft Risk Hub
- Chrome extension
Resources
© Craft.co 2026